Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
March 22 2021 - 6:30AM
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader
in gene and cell therapy, today announced that Michael Amoroso,
Executive Vice President, Chief Operating Officer (COO) and
principal executive officer at Abeona, has been promoted to
President, Chief Executive Officer (CEO) and a member of the
company’s Board of Directors, effective immediately.
“Michael’s promotion to CEO reflects his
unwavering commitment and outstanding operational leadership during
a period of important transition for the company, and the Board
fully supports him and the Abeona senior management team,” said
Steven H. Rouhandeh, Chairman of Abeona’s Board of Directors.
“Under Michael’s stewardship, Abeona has remained focused on the
strategy of providing our novel gene and cell therapies to patients
who currently have no approved treatment options, delivering on
meaningful milestones across our three clinical development
programs during the last six months.”
Most recently, Mr. Amoroso has been responsible
for overseeing the operational management of Abeona, including
research and clinical development, regulatory, medical, commercial,
corporate affairs and business development as COO and principal
executive officer. Mr. Amoroso joined Abeona in 2020, bringing
extensive experience in leading teams across clinical development,
regulatory and medical affairs, corporate affairs, and commercial,
both in the U.S and globally, with direct operational experience in
major world markets. For 20 years, he has led and been part of
teams responsible for launches and delivering profit and loss
results for major biopharmaceutical products across most
therapeutic areas. Mr. Amoroso has worked with companies in the
small molecule, biologic, and cell and gene therapy spaces, with
his deepest areas of expertise in rare oncological diseases.
Prior to joining Abeona, Mr. Amoroso held
various senior level executive positions at leading
biopharmaceutical companies, including Kite, Eisai Inc., Celgene
Corporation (now a subsidiary of Bristol-Myers Squibb Company), and
began his biopharmaceutical career at Aventis (now Sanofi). Mr.
Amoroso earned his Executive M.B.A. in Management from the Stern
School of Business, New York University, and his B.A. in Biological
Sciences, summa cum laude, from Rider University.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage
biopharmaceutical company developing gene and cell therapies for
serious diseases. Abeona’s clinical programs include EB-101, its
autologous, gene-corrected cell therapy for recessive dystrophic
epidermolysis bullosa in Phase 3 development, as well as ABO-102
and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome
types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2
development. The Company’s portfolio also features AAV-based gene
therapies for ophthalmic diseases with high unmet medical needs.
Abeona’s novel, next-generation AIM™ capsids have shown potential
to improve tropism profiles for a variety of devastating diseases.
Abeona’s fully functional, gene and cell therapy GMP manufacturing
facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and
is capable of clinical and commercial production of AAV-based gene
therapies. For more information, visit
www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements
that are forward-looking within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and that involve risks
and uncertainties. These statements include statements about the
Company exploring all strategic options, including the sale of some
or all of its assets or sale of the Company. We have attempted to
identify forward-looking statements by such terminology as “may,”
“will,” “believe,” “estimate,” “expect,” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances), which constitute and are intended to
identify forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, numerous risks and
uncertainties, including but not limited to the potential impacts
of the COVID-19 pandemic on our business, operations, and financial
condition, the outcome of the Company’s ongoing strategic review,
continued interest in our rare disease portfolio, our ability to
enroll patients in clinical trials, the outcome of any future
meetings with the U.S. Food and Drug Administration or other
regulatory agencies, the impact of competition, the ability to
secure licenses for any technology that may be necessary to
commercialize our products, the ability to achieve or obtain
necessary regulatory approvals, the impact of changes in the
financial markets and global economic conditions, risks associated
with data analysis and reporting, and other risks disclosed in the
Company’s most recent Annual Report on Form 10-K and subsequent
quarterly reports on Form 10-Q and other periodic reports filed
with the Securities and Exchange Commission. The Company undertakes
no obligation to revise the forward-looking statements or to update
them to reflect events or circumstances occurring after the date of
this press release, whether as a result of new information, future
developments or otherwise, except as required by the federal
securities laws.
Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
+1 (646) 813-4709
ggin@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Oct 2023 to Oct 2024